Skip to content

Sleep and Saliva: A Look at Antioxidant Capacity in Children

Evaluation of Salivary Total Antioxidant Capacity in Children with and without Sleep disorders: A Pilot Study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/06/089047
Enrollment
70
Registered
2025-06-18
Start date
Unknown
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Nil: Nil

Sponsors

Dr Isha Gore
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Inclusion criteria for Study group - 1. Children of either gender aged 6 to 11 years 2. Children with skeletal class II malocclusion with retrognathic mandible requiring myofunctional therapy, as determined by detailed. cephalometric assessment. 3. Children with at least one sleep problem as determined by a validated sleep questionnaire. INCLUSION CRITERIA FOR THE CONTROL GROUP (Group 2): 1. Children of either gender aged 6-11 years. 2. Children with no history of sleep problems.

Exclusion criteria

Exclusion criteria: EXCLUSION CRITERIA FOR BOTH GROUPS: 1. Children with systemic and neurological disorders and/or cognitive deficit. 2. Children on medications that may affect their oral health. 3. Children who have undergone professional fluoride treatment. 4. Children who use an antimicrobial mouth rinse.

Design outcomes

Primary

MeasureTime frame
The primary outcomes of this are the salivary total antioxidant capacity, resting salivary pH and salivary buffering capacity measured in children with and without sleep disorders.Timepoint: Baseline

Secondary

MeasureTime frame
NILTimepoint: NIL

Countries

India

Contacts

Public ContactIsha Gore

NItte (Deemed to be university) AB Shetty Memorial Institute of Dental Sciences

docvabitha29@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026